Navigation Links
Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
Date:12/17/2009

so includes several years with Immune Mediated Disease, Vertex Pharmaceuticals Incorporated, Amgen Inc. and Merck Human Health.

Ms. Lauterbach received her Bachelor of Science in Molecular Biology from the University of Wisconsin and her Masters in Business Administration from the University of South Florida.

About Protalix

Protalix is a biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins expressed through its proprietary plant cell based expression system. Protalix's ProCellEx(TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins in an environment free of mammalian components and viruses. Protalix is also advancing additional recombinant biopharmaceutical drug development programs. Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol Assessment with the U.S. Food and Drug Administration for Gaucher disease.

Safe Harbor Statement:

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause material differences include, among others, risks relating to: the successful preclinical development of our product candidates; the completion of clinical trials; the review process of the FDA, foreign regulatory bodi
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
2. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
3. CVS Caremark Names New Chief Human Resources Officer
4. Cardinal Health Names Carrie Cox to Board of Directors
5. Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO
6. The Deal Names Abbott Top Dealmaker for Second Consecutive Year
7. IDEV Technologies Names Christopher M. Owens President, Chief Executive Officer
8. AMD LASERS Names Dr. James Jesse as Medical Director
9. Arcadia Resources Names Stephen Goldsmith to Board of Directors
10. NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations
11. Codexis Names Fernando Valle Research Fellow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Magnaquest, a leading Subscription ... cloud computing operators has signed a Proof of ... Internet of Things (IoT) related initiative. The PoC ... model.      (Logo: http://photos.prnewswire.com/prnh/20140807/700645 ) ... business innovations to make healthcare services more accessible ...
(Date:7/30/2015)...  ResMed Inc. (NYSE: RMD ) today announced ... for the quarter was $453.1 million, a 9 percent ... (a 17 percent increase on a constant currency basis). ... ended June 30, 2014.  Diluted earnings per share for ... June 30, 2014.  The results for ...
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... MedImmune today announced,that it has initiated a Phase 1/2a ... children one month to 12 months of age to,help ... most common respiratory infection in infants and can cause ... a serious respiratory disease that can have significant effects,on ...
... Partner to Make Direct Investment in CEL-SCI, ... CVM ) announced today that it has expanded ... Co., Ltd. ("Orient,Europharma"), a leading pharmaceutical company from ... also cover South Korea,the Philippines, Australia and New ...
Cached Medicine Technology:MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine 2CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 2CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 3
(Date:7/31/2015)... ... 31, 2015 , ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company ... , BioViva announces it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to ... a cure. MaxLife will grant 100% of the money raised to BioViva to help ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Heart Fit Clinic has increased a patient's ... heart rate of 150 beats versus 100 beats, this is a big deal," says ... give life back to patients with heart disease," he adds. People with angina are ...
(Date:7/31/2015)... York, NY (PRWEB) , ... July 31, 2015 , ... ... kidney disease, according to a study published today in Nature Communications and led by ... conducted in mice, suggests that variations in the gene RTN1 led to greater production ...
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased ... in Q-Suite 5.9. Q-Suite is their flagship contact center ACD system for Asterisk-based ... script display logic shows the script components to the agent only when wanted, and ...
(Date:7/31/2015)... ... , ... According to WFLA on July 16th, Sarasota has seen ... overdoses. Thricefold deaths have held steady over the last “couple of months” according to ... which was spurred by the crackdown of prescription painkillers. Many users who were addicted ...
Breaking Medicine News(10 mins):Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3
... reason to deny insurers access to genetic information, argues a ... BMJ. ,Only if we refuse to give ... them seeking genetic test results, says Professor Soren Holm from ... to any health information they would only be able to ...
... of herbal products and medicines has the potential to reach ... the creation of exclusive export promotion zones (EPZ) across ... can be accelerated with the setting up of EPZs in ... rate of over 25 percent in countries like the US, ...
... less than three dollars a year per patient could ... from the trauma and torment of epilepsy, a new ... 85 percent of epilepsy sufferers in the developing world ... the drugs most often prescribed to impede the terrible ...
... find the perfect present this Father's Day? What better way to ... keep him healthy and vital for years to come . This ... check themselves out -- and then get checked out by their ... and over have diabetes. The symptoms of type 2 diabetes, the ...
... getting rid of smoking was more difficult for him than ... ,The former hellraiser, who quit his nicotine addiction in ... hooked to smoking again.,He revealed that before he had kicked ... ,"They're all a b**ger to kick, but I'd ...
... with Prof Vijay K Varadan, an Indian born US ... production of ``glucose watches''. The talks are in the ... ,Varadan holds the post of Director of the Centers ... Density Electronics Center (HiDEC) and Neurosurgery Research Programme in University ...
Cached Medicine News:Health News:Should Genetic Information Be Disclosed to Insurers? 2Health News:Export of Herbal Products to Reach Rs.120 Billion by 2012: Study 2Health News:Small Change Could Stop Epilepsy Seizures for Millions 2Health News:Drag Dad to the Doctor This Father's Day 2Health News:Titan may Produce Glucose Watches Soon 2
Are you looking for an inexpensive, effective Blood and Infusion Warmer? , ,Animec is an economical fluid warmer that uses standard I.V. tubing instead of special disposable sets....
... The reliable, rugged and easy-to-use solution that's ... is required., ,Symeon's light weight and ... moved into any working position. It can ... And excessive cable "spaghetti syndrome" is minimized ...
... Narkomed 6400 Series anesthesia workstation provides ... technologies are combined to provide true ... user. State of the art computer ... onto a single color touchscreen display ...
... Developed to be used in facilities where ... the latest ventilation and gas delivery technologies ... the ability and the functionality of the ... to create yourself a workplace environment that ...
Medicine Products: